A phase I study of decitabine with pegylated interferon α-2b in advanced melanoma: Impact on DNA methylation and lymphocyte populations

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 969-975

  Plimack, E R ^a   Desai, J R ^b   Issa, J P ^c   Jelinek, J ^c   Sharma, P ^d   Vence, L M ^d   Bassett, R L ^d   Ilagan, J L ^d   Papadopoulos, N E ^d   Hwu, W J ^d  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Decitabine; Epigenetic therapy; Immunotherapy; Interferon; Melanoma

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; AZACITIDINE; DECITABINE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT PROTEIN;

AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; DNA METHYLATION; FEMALE; HUMAN; IMMUNOLOGY; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; METABOLISM; MIDDLE AGED; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; T LYMPHOCYTE SUBPOPULATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; DNA METHYLATION; FEMALE; HUMANS; INTERFERON-ALPHA; LEUKOCYTE COUNT; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEUTROPENIA; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS;

EID: 84939875915     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0115-4     Document Type: Article

References (19)

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E (2012) Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62(4):220-241. doi:10.3322/caac.21149
2. Hu W, Jin L, Jiang CC, Long GV, Scolyer RA, Wu Q, Zhang XD, Mei Y, Wu M (2013) AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma. Cell Death Dis 4:e914. doi:10.1038/cddis.2013.441
3. Robert C, Thomas L, Bondarenko I, O'Day S, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A,Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26):2517-2526. doi:10.1056/NEJMoa1104621
4. Merkel DG, Nagler A (2013) The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm. Expert Rev Hematol. doi:10.1586/17474086.2013.854699
5. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, Renard J, van Glabbeke M, Pinedo HM (1987) The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol 23(12):1921-1924
6. Tawbi HA (2013) Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol 24(4):8. doi:10.1093/annonc/mds591
7. Dummer R, Garbe C, Thompson JA, Eggermont AM, Yoo K, Maier T, Bergstrom B (2006) Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 24(7):1188-1194
8. Guillot B, Khamari A, Cupissol D, DelaunayM, Bedane C, Dreno B, Picot MC, Dereure O (2008) Temozolomide associated with PEG-interferon in patients with metastatic melanoma: a multicenter prospective phase I/II study. Melanoma Res 18(2):141-146. doi:10.1097/CMR.0b013e3282f6309c
9. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC (2006) Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol Off J Am Soc Clin Oncol 24(23):3771-3779. doi:10.1200/jco.2005.03.4074
10. Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34-55
11. Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5(10):2726-2734
12. Fonsatti E, Nicolay HJ, Sigalotti L, Calabro L, Pezzani L, Colizzi F, Altomonte M, Guidoboni M, Marincola FM, Maio M (2007) Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin Cancer Res Off J Am Assoc Cancer Res 13(11):3333-3338. doi:10.1158/1078-0432.ccr-06-3091
13. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP (2004) A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 32(3):e38
14. Lal G, Zhang N, van der Touw W, Ding Y, JuW, Bottinger EP, Reid SP, Levy DE, Bromberg JS (2009) Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol 182(1):259-273
15. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-57. doi:10.1182/blood-2006-05-021162
16. Stewart DJ, Issa JP,Kurzrock R, NunezMI, Jelinek J,Hong D,OkiY, Guo Z, Gupta S,Wistuba II (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin Cancer Res 15(11):3881-3888. doi:10.1158/1078-0432.CCR-08-2196
17. Triozzi P, Aldrich W, Achberger S, Ponnazhagan S, Alcazar O, Saunthararajah Y (2012) Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice. Cancer Immunol Immunother 61(9):1441-1450. doi:10.1007/s00262-012-1204-x
18. Juergens RA,Wrangle J, Vendetti FP, Murphy SC, ZhaoM, Coleman B, Sebree R, Rodgers K, Hooker CM, Franco N, Lee B, Tsai S, Delgado IE, RudekMA, Belinsky SA, Herman JG, Baylin SB, Brock MV, Rudin CM (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Disc. doi:10.1158/2159-8290.cd-11-0214
19. Tsai H-C, Li H, Van Neste L, Cai Y, Robert C, Rassool Feyruz V, Shin James J, Harbom Kirsten M, Beaty R, Pappou E, Harris J, Yen R-Whay C, Ahuja N, Brock Malcolm V, Stearns V, Feller-Kopman D, Yarmus Lonny B, Lin Y-C, Welm Alana L, Issa J-P, Minn I, Matsui W, Jang Y-Y, Sharkis Saul J, Baylin Stephen B, Zahnow Cynthia A (2012) Transient low doses of dna-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3):430-446. doi:10.1016/j.ccr.2011.12.029